Infectious Disease, Options Prevalent In 2014 Start-Up Dealmaking
This article was originally published in Start Up
Executive Summary
The number of deals signed by biopharma start-ups increased 7% in 2014, which featured a bump in partnerships for infectious disease drugs and multiple option-to-acquire agreements.